Eli Lilly and Company (LLY)
| Market Cap | 952.29B |
| Revenue (ttm) | 59.42B |
| Net Income (ttm) | 18.41B |
| Shares Out | 895.38M |
| EPS (ttm) | 20.44 |
| PE Ratio | 52.03 |
| Forward PE | 33.76 |
| Dividend | $6.92 (0.65%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 2,526,304 |
| Open | 1,086.83 |
| Previous Close | 1,085.19 |
| Day's Range | 1,063.03 - 1,104.52 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 1,104.11 (+3.81%) |
| Earnings Date | Feb 5, 2026 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,104.11, which is an increase of 3.81% from the latest price.
News
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections...
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company a...
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.
Lilly's Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Tal...
Pharma stocks are set to take off this year, says UBS' Michael Yee
Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
Eli Lilly will buy Ventyx Biosciences in an all-cash deal worth $1.2 billion, the companies said on Wednesday, marking the Zepbound maker's latest push to expand beyond its blockbuster diabetes and we...
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-me...
Eli Lilly's 2026 Resolution: Volume Is The New Price
Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over ne...
Lilly in talks to buy Ventyx Biosciences in more than $1 billion deal, WSJ reports
Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter
The more-than-$1 billion deal could come imminently.
Eli Lilly, Nimbus Partner to Develop, License Oral Obesity Treatment
Eli Lilly and Nimbus Therapeutics have entered into a multiyear collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.
Nimbus, Lilly sign deal to develop new oral obesity drug
Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to develop artificial intelligence-driven new oral treatments for obesity and other...
Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum
Eli Lilly (LLY) remains a Strong Buy, driven by robust GLP-1 demand and stellar execution, delivering a 34% total return since initial bullish coverage. LLY's Q3 results showed a 10% revenue and 19% E...
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Top 15 High-Growth Dividend Stocks For January 2026
My Top 15 High-Growth Dividend Stock list delivered a 0.83% gain in December, outperforming SPY and VIG. The Value-tilted portfolio variant led with a 2.17% December return, suggesting undervaluation ...
In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
GLP-1 weight-loss pills set to reshape US food demand in 2026
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in Jan...
Focus: Lilly, Novo lock horns in India's obesity drug race
Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.
US health agency to expand access to GLP-1 weight-loss drugs
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback
As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two names capture that shift better than Eli Lilly And Co (NYSE: LLY) and Novo Nord...